Revenue segments as reported by the company.

Dialysis patient service revenues

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Depreciation and amortization

Equity investment income (loss), net

Loss (gain) on changes in ownership interest, net

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DaVita

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DaVita reports robust Q4 earnings, navigates challenges with strategic focus

DaVita's Q4 2022 performance reflects financial strength and operational improvements, supported by strategic initiatives and cost discipline.
While facing challenges in operational dynamics and market uncertainties, DaVita remains focused on growth opportunities and patient-centric care.
The company's outlook for 2023 shows a commitment to long-term success through innovation, efficiency, and resilience in a changing healthcare landscape.

DaVita reports strong Q1 earnings and innovation in kidney health

DaVita's Q1 2023 earnings call highlighted strong financial performance, operational efficiency, and a focus on patient care, positioning the company well for future growth and success.
While challenges such as limited operational details and potential labor management issues exist, DaVita's strengths in cost management, innovation, and patient-centric care present opportunities for sustained performance.
Overall, DaVita's positive momentum, revised financial outlook, and commitment to enhancing healthcare services indicate a promising trajectory for the company in the competitive healthcare landscape.

DaVita reports strong Q2 earnings, navigates CMS challenges effectively

DaVita's Q2 2023 performance reflects resilience amidst challenges, with a focus on innovation and operational efficiencies.
The company faces industry headwinds but remains committed to driving growth and enhancing patient care.
Analysts' questions highlighted key concerns and opportunities, showcasing DaVita's proactive approach to addressing industry dynamics.
Overall, DaVita's strategic focus on performance and stakeholder communication positions the company for continued success.

DaVita reports robust Q3 performance and eyes growth opportunities

DaVita's Q3 2023 Earnings Call highlighted strong financial results, operational priorities, and growth prospects. Despite challenges in managing drug impacts and market perception, the company remains focused on delivering quality care and driving shareholder value. Opportunities in CKD progression, shareholder returns, and IKC business improvement position DaVita for future success.

DaVita surpasses 2023 guidance, eyes growth and efficiency in 2024

DaVita's Q4 2023 Earnings Call showcased strong financial performance, exceeding guidance and highlighting a focus on efficiency and cost savings.
While facing challenges like legal proceedings and capacity utilization, DaVita remains optimistic about financial recovery and growth opportunities in 2024.
The company's successful Integrated Kidney Care program and commitment to driving operating performance position it well for continued success in the healthcare market.

DaVita reports robust Q1 earnings, eyes international expansion opportunities

DaVita's Q1 2024 performance reflects strong financial results and a strategic focus on kidney care solutions and international growth.
While challenges like the Change Healthcare outage were addressed, opportunities in expanding markets and enhancing patient care services are evident.
Management's commitment to quality care and sustainable growth positions DaVita well for continued success in the healthcare sector.

DaVita reports robust Q2 earnings, supports CMS proposal for growth

DaVita's Q2 2024 earnings call highlighted strong financial performance and strategic initiatives to drive growth.
While facing challenges in certain operational areas, the company's proactive stance on policy advocacy and financial guidance raise optimism.
Opportunities lie in optimizing operational metrics, managing costs effectively, and engaging stakeholders for sustained growth.

DaVita maintains financial course amidst challenges, eyes growth opportunities

DaVita's Q3 performance met expectations despite supply chain disruptions, with full-year guidance reaffirmed.
The company faces short-term challenges from hurricane impacts and regulatory uncertainties.
Opportunities lie in market changes and growth initiatives, though long-term guidance remains pending.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DaVita HealthCare (DVA) reachead $137.72 at the closing of the latest trading day, reflecting a +1.3% change compared to its last close.

DaVita HealthCare (DVA) Rises Higher Than Market: Key Facts

DaVita's (DVA) shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.

DaVita (DVA) Gains 29.8% YTD: What's Driving the Stock?

Medtronic

Renal Denervation Devices Market Size, Share & Trends Analysis Report By Technology (Radiofrequency-based, Ultrasound-based, Micro-infusion-based, Others), By End User (Hospitals & Clinics, Ambulatory surgery centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032 Renal Denervation Devices Market Size, Share & Trends Analysis Report By Technology (Radiofrequency-based, Ultrasound-based, Micro-infusion-based, Others), By End User (Hospitals & Clinics, Ambulatory surgery centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Renal Denervation Devices Market Expected to Reach USD 387 Million by 2032 with a Remarkable 37.2% CAGR, According to Straits Research

Fresenius Medical Care

The U.S. Federal Trade Commission (FTC) is investigating healthcare providers DaVita and Fresenius Medical Care over allegations that the companies have been illegally thwarting smaller competitors, Politico reported on Saturday, citing three people familiar with the matter.

US FTC probing DaVita, Fresenius Medical, Politico reports

DaVita's (DVA) strength in its kidney care raises optimism about the stock.

Here's Why You Should Add DaVita (DVA) to Your Portfolio

DaVita HealthCare (DVA) concluded the recent trading session at $137.92, signifying a +0.39% move from its prior day's close.

DaVita HealthCare (DVA) Surpasses Market Returns: Some Facts Worth Knowing

DaVita's (DVA) strength in its kidney care segment raises optimism about the stock.

Here's Why You Should Add DaVita (DVA) to Your Portfolio Now

In the latest trading session, DaVita HealthCare (DVA) closed at $142.16, marking a -0.53% move from the previous day.

DaVita HealthCare (DVA) Stock Slides as Market Rises: Facts to Know Before You Trade

DaVita HealthCare (DVA) closed the most recent trading day at $140.24, moving -1.39% from the previous trading session.

DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note

DaVita HealthCare (DVA) reachead $142.16 at the closing of the latest trading day, reflecting a -0.37% change compared to its last close.

DaVita HealthCare (DVA) Stock Declines While Market Improves: Some Information for Investors

Eldorado Gold

Sasol

Invest in shares of Eldorado Gold (EGO), Sasol (SSL) and DaVita (DVA) that hold huge upside potential.

3 PEG-Based Value Picks to Boost Your Portfolio Returns

DaVita's (DVA) shares have risen year to date on the back of strong performance and the acquisition of dialysis centers.

DaVita (DVA) Gains 36% YTD: What's Driving the Stock Rally?

Kroger

Occidental Petroleum

“Price is what you pay; value is what you get.” In 2008, Warren Buffett told Berkshire Hathaway (NYSE: BRK-A , BRK-B ) shareholders that buying good businesses when they're cheap was the quintessential way to amass wealth.

Buffett Buys on a Budget: The 3 Cheapest Stocks Held by Berkshire Hathaway

 Nuwellis

DaVita DVA recently extended the pilot phase of a previously announced supply and collaboration agreement with Nuwellis NUWE until Aug 31, 2024.At the conclusion of the pilot phase, DaVita may extend the supply agreement with Nuwellis for continued provision of both inpatient and outpatient ultrafiltration services for up to 10 years.

DaVita, Nuwellis Extend Pilot Collaboration for Aquadex

American Express

CareCloud Inc

RadNet

SkyWest

With service sector activity rebounding in recent times, it's worth placing bets on stocks such as CareCloud (CCLD), DaVita (DVA), RadNet (RDNT), SkyWest (SKYW) and American Express (AXP).

5 Stocks to Gain as Service Side of the Economy Bounces Back

DaVita (DVA) extends its pilot collaboration with Nuwellis to conduct additional testing of the Aquadex ultrafiltration treatment for adult patients suffering from congestive heart failure and related conditions.

DaVita (DVA), Nuwellis Extend Pilot Collaboration for Aquadex

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why DaVita HealthCare (DVA) is a Strong Momentum Stock

Louisiana-Pacific

Nu Holdings

Though investors of a different variety – such as Roaring Kitty of the GameStop (NYSE: GME) meme stock craze fame – have become increasingly popular in recent years, old-school investing legends have retained their prominent position among stock market aficionados.

These Warren Buffett stocks are crushing the S&P 500 in 2024

The latest trading day saw DaVita HealthCare (DVA) settling at $143.18, representing a -0.46% change from its previous close.

DaVita HealthCare (DVA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Mitsui & Co Ltd

Nu Holdings stock skyrocketed in Q1 and remains Buffett's biggest winner this year. DaVita is expanding internationally.

These Warren Buffett Stocks Are Trouncing the S&P 500 so Far This Year. Are They Still Buys?

Burlington Stores

Dropbox

MGM Resorts

Sterling Construction

Top-ranked stocks MGM Resorts International (MGM), Burlington Stores (BURL), Sterling Infrastructure Inc (STRL), Dropbox (DBX) and DaVita (DVA) are likely to beat on the bottom line in their upcoming releases.

Play Likely Earnings Beat With These 5 Top-Ranked Stocks

Investors are optimistic about DaVita's (DVA) strength in kidney care.

DaVita (DVA) Hits 52-Week High: What's Aiding the Stock?

DaVita (DVA) Gains 34.5% YTD: What's Driving the Stock?

DENVER , May 14, 2024 /PRNewswire/ -- Today, DaVita (NYSE: DVA) published its 2023 Community Care Report, underscoring its dedication to corporate social responsibility and commitment to setting a new standard for health care services. DaVita's annual Community Care Report examines progress toward its 2025 Environmental, Social, and Governance (ESG) goals to help improve the lives of patients and support the health of communities globally.

DaVita Celebrates Corporate Citizenship Achievements with Release of 2023 Community Care Report

Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita  DENVER , May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms.

News for DaVita Stock (DVA)